Hims & Hers Opposes Novo Nordisk Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 09 2026
0mins
Should l Buy HIMS?
Hims & Hers (HIMS) said in a post on X, formerly Twitter: "Novo Nordisk's (NVO) lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care. Once again, Big Pharma is weaponizing the US judicial system to limit consumer choice. This lawsuit attacks more than just one medication or company - it directly assaults a well-established, vital component of US pharmacy practice that has improved patient care for everything from obesity to infertility to cancer. Hims & Hers has a long history of providing safe access to personalized healthcare to millions of Americans, and we will continue to fight to provide choice, affordability, and access."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 19.380
Low
16.50
Averages
32.95
High
60.00
Current: 19.380
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Launches Novo Nordisk Weight Loss Medications
- Increased Medication Accessibility: Hims & Hers Health Inc. announced a collaboration with Novo Nordisk to make FDA-approved GLP-1 medications like Wegovy and Ozempic more accessible, potentially aiding eligible customers in losing up to 20% of their body weight, thereby significantly improving their health outcomes.
- Diverse Dosage Options: The newly launched Wegovy medications include various dosage options such as injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, along with oral medications in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, catering to different customer needs and enhancing market competitiveness.
- Membership Program Launch: The company has introduced a new weight loss membership program that offers 24/7 access to healthcare providers, personalized nutrition guidance, and peer support, with an initial cost of $39 for the first month and $149 thereafter, aimed at increasing customer success rates in weight loss through comprehensive support.
- Transparent Pricing: Medication prices start at $149 per month, and customers can utilize HSA and FSA plans to cover medication costs, enhancing payment flexibility and attracting more potential users to join the membership program.
See More
HIMS Launches Multiple Weight Loss Medications and Membership Service
- Diverse Drug Dosing: HIMS has launched Wegovy with injection doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, with a 7.2 mg dose to follow, aiming to cater to various patient needs and enhance market competitiveness.
- Innovative Membership Service: The new weight-loss membership starts at $39 for the first month and $149 thereafter, offering 24/7 medical support and personalized nutrition guidance, which is designed to increase customer retention and create a sustainable revenue stream.
- Legal Dispute Resolution: Following Novo Nordisk's withdrawal of its patent infringement lawsuit against HIMS, a partnership was formed allowing HIMS to offer FDA-approved Wegovy and Ozempic at lower self-pay prices, demonstrating the company's adaptability in compliance and market strategy.
- Market Reaction Analysis: Despite HIMS stock declining approximately 37% year-to-date, the collaboration with NVO may improve its market perception, although retail investor sentiment remains bearish, indicating cautious outlooks on future performance.
See More
Hims & Hers Launches Novo Nordisk GLP-1 Medications for Weight Loss
- Product Launch: Hims & Hers Health has commenced sales of Novo Nordisk's GLP-1 medications Wegovy and Ozempic, offering all injectable strengths and the Wegovy pill, which is expected to significantly enhance the company's competitiveness in the weight loss and diabetes treatment markets.
- Membership Service Introduction: The company has launched a new weight loss membership service that provides 24/7 access to providers, personalized nutrition guidance, and clinical check-ins, with an introductory fee of $39 for the first month and $149 thereafter, aimed at increasing customer loyalty and revenue through value-added services.
- Pricing Strategy: The Wegovy injection is priced at $199 per month, with the pill at $149, while Ozempic also starts at $199 per month; this pricing strategy is designed to help the company achieve profitability in a high-demand market.
- Legal Dispute Resolution: Hims & Hers has resolved its dispute with Novo Nordisk, allowing the former to sell compounded versions of semaglutide under very limited circumstances, providing the company with more flexibility to meet market demands.
See More
Hims & Hers Launches FDA-Approved Weight Loss Medications
- Increased Medication Access: Hims & Hers, in collaboration with Novo Nordisk, has launched a range of FDA-approved GLP-1 medications, including the only weight loss pill Wegovy®, enabling eligible customers to access these treatments at more affordable prices, which is expected to significantly enhance their health management capabilities.
- Weight Loss Potential: Eligible customers can lose up to 20% of their body weight using Wegovy® under clinical guidance, which, combined with diet and exercise, is anticipated to improve overall health outcomes and strengthen brand loyalty among users.
- New Membership Program: Hims & Hers has introduced a new weight loss membership plan that includes comprehensive support services such as 24/7 direct access to providers and personalized nutrition guidance, with an initial fee of $39 for the first month and $149 thereafter, aimed at increasing customer success rates through ongoing support.
- Market Leadership: This expansion positions Hims & Hers as the largest global consumer health platform offering affordable access to FDA-approved medications, further solidifying its leadership in the health management sector and driving future business growth.
See More
HIMS & HERS HEALTH INC LAUNCHES WEIGHT LOSS MEMBERSHIP WITH INITIAL MONTH AT $39, FOLLOWED BY $149 PER MONTH
- Membership Introduction: HIMS & HERS has launched a new weight loss membership program.
- Pricing Structure: The membership starts at $39 for the first month and $149 thereafter.
See More
HIMS & HERS HEALTH INC - GLP-1 MEDICATIONS AVAILABLE FROM $149 A MONTH
- Medication Pricing: The medication "HIMS & HERS HEALTH INC - GLP-1" is priced at $149 per month.
- Market Introduction: This pricing indicates the company's entry into the market for GLP-1 medications, which are used for various health conditions.
See More
Hims & Hers Launches Novo Nordisk Weight Loss Medications
- Increased Medication Accessibility: Hims & Hers Health Inc. announced a collaboration with Novo Nordisk to make FDA-approved GLP-1 medications like Wegovy and Ozempic more accessible, potentially aiding eligible customers in losing up to 20% of their body weight, thereby significantly improving their health outcomes.
- Diverse Dosage Options: The newly launched Wegovy medications include various dosage options such as injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, along with oral medications in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, catering to different customer needs and enhancing market competitiveness.
- Membership Program Launch: The company has introduced a new weight loss membership program that offers 24/7 access to healthcare providers, personalized nutrition guidance, and peer support, with an initial cost of $39 for the first month and $149 thereafter, aimed at increasing customer success rates in weight loss through comprehensive support.
- Transparent Pricing: Medication prices start at $149 per month, and customers can utilize HSA and FSA plans to cover medication costs, enhancing payment flexibility and attracting more potential users to join the membership program.
See More
HIMS Launches Multiple Weight Loss Medications and Membership Service
- Diverse Drug Dosing: HIMS has launched Wegovy with injection doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, with a 7.2 mg dose to follow, aiming to cater to various patient needs and enhance market competitiveness.
- Innovative Membership Service: The new weight-loss membership starts at $39 for the first month and $149 thereafter, offering 24/7 medical support and personalized nutrition guidance, which is designed to increase customer retention and create a sustainable revenue stream.
- Legal Dispute Resolution: Following Novo Nordisk's withdrawal of its patent infringement lawsuit against HIMS, a partnership was formed allowing HIMS to offer FDA-approved Wegovy and Ozempic at lower self-pay prices, demonstrating the company's adaptability in compliance and market strategy.
- Market Reaction Analysis: Despite HIMS stock declining approximately 37% year-to-date, the collaboration with NVO may improve its market perception, although retail investor sentiment remains bearish, indicating cautious outlooks on future performance.
See More
Hims & Hers Launches Novo Nordisk GLP-1 Medications for Weight Loss
- Product Launch: Hims & Hers Health has commenced sales of Novo Nordisk's GLP-1 medications Wegovy and Ozempic, offering all injectable strengths and the Wegovy pill, which is expected to significantly enhance the company's competitiveness in the weight loss and diabetes treatment markets.
- Membership Service Introduction: The company has launched a new weight loss membership service that provides 24/7 access to providers, personalized nutrition guidance, and clinical check-ins, with an introductory fee of $39 for the first month and $149 thereafter, aimed at increasing customer loyalty and revenue through value-added services.
- Pricing Strategy: The Wegovy injection is priced at $199 per month, with the pill at $149, while Ozempic also starts at $199 per month; this pricing strategy is designed to help the company achieve profitability in a high-demand market.
- Legal Dispute Resolution: Hims & Hers has resolved its dispute with Novo Nordisk, allowing the former to sell compounded versions of semaglutide under very limited circumstances, providing the company with more flexibility to meet market demands.
See More
Hims & Hers Launches FDA-Approved Weight Loss Medications
- Increased Medication Access: Hims & Hers, in collaboration with Novo Nordisk, has launched a range of FDA-approved GLP-1 medications, including the only weight loss pill Wegovy®, enabling eligible customers to access these treatments at more affordable prices, which is expected to significantly enhance their health management capabilities.
- Weight Loss Potential: Eligible customers can lose up to 20% of their body weight using Wegovy® under clinical guidance, which, combined with diet and exercise, is anticipated to improve overall health outcomes and strengthen brand loyalty among users.
- New Membership Program: Hims & Hers has introduced a new weight loss membership plan that includes comprehensive support services such as 24/7 direct access to providers and personalized nutrition guidance, with an initial fee of $39 for the first month and $149 thereafter, aimed at increasing customer success rates through ongoing support.
- Market Leadership: This expansion positions Hims & Hers as the largest global consumer health platform offering affordable access to FDA-approved medications, further solidifying its leadership in the health management sector and driving future business growth.
See More
HIMS & HERS HEALTH INC LAUNCHES WEIGHT LOSS MEMBERSHIP WITH INITIAL MONTH AT $39, FOLLOWED BY $149 PER MONTH
- Membership Introduction: HIMS & HERS has launched a new weight loss membership program.
- Pricing Structure: The membership starts at $39 for the first month and $149 thereafter.
See More
HIMS & HERS HEALTH INC - GLP-1 MEDICATIONS AVAILABLE FROM $149 A MONTH
- Medication Pricing: The medication "HIMS & HERS HEALTH INC - GLP-1" is priced at $149 per month.
- Market Introduction: This pricing indicates the company's entry into the market for GLP-1 medications, which are used for various health conditions.
See More
